Navigation Links
Barrett Katz, MD, MBA, Named CEO of Danube Pharmaceuticals
Date:6/18/2008

NEW YORK, June 18 /PRNewswire/ -- Danube Pharmaceuticals, Inc., a privately held biopharmaceutical company specializing in the commercial research and development of innovative drugs for ophthalmology, is pleased to announce the appointment of Dr. Barrett Katz, MD, MBA as its Chief Executive Officer.

"I am honored and delighted to join Danube Pharmaceuticals at this inflection point in its history as it advances its lead programs through clinical trials and brings novel bench research to the clinics and bedside," said Barrett Katz, MD, MBA, Chief Executive Officer of Danube.

"We are delighted to welcome Dr. Katz to our team," said David R. Guyer, MD, Chairman of Danube. "His leadership, energy and experience will transform our senior management team and complement the clinical and managerial talents we have. His outstanding reputation in the international ophthalmology community coupled with his expertise in the field of drug development, drug approval and product launch will be invaluable for bringing Danube's product candidates from clinical trials to market effectively and efficiently."

Dr. Katz is a renowned ophthalmologist with over 25 years of experience in clinical trials and medical strategy, drug development and regulatory issues. Prior to joining Danube, Dr. Katz served as Executive Vice President and Chief Medical Officer of Fovea Pharmaceuticals SA, in Paris. Before that he was Vice President for Medical Affairs and Medical Strategy at Eyetech Pharmaceuticals, and had been integral to the team that developed Macugen(TM) and brought it to market.

Dr. Katz also served as Professor of Ophthalmology, Neurology and Neurosurgery, and as the Chairman of the Department of Ophthalmology at The George Washington University School of Medicine in Washington, D.C. While there, he formulated and sponsored a joint fellowship in Ophthalmology drug development, clinical trials, and regulatory affairs with the U.S. Food and Drug Administ
'/>"/>

SOURCE Danube Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
2. Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences
3. Netsmarts Kevin Scalia Named Chair of the Software and Technology Vendors Association
4. GlaxoSmithKline Named A Top Employer for Promoting Healthy Lifestyles
5. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
6. President and CEO of Velcura Therapeutics Inc. Named the 2008 Grant Thornton Leader and Innovator of the Year
7. Black Box Network Services, ABTECH, Verizon Business and Wyle Named Top Siemens Reseller Partners
8. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
9. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
10. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
11. James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... down the product choices to a manageable shortlist of bench and floor scales ... models that fit best with the customer’s industry and application. , Side-by-side ...
(Date:8/26/2015)... Manhattan, KS (PRWEB) , ... August 26, 2015 ... ... & Biologic Solutions, announces today that a second US laboratory is to open ... in accordance with the continued partnership and long-term growth of research and development ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... its investment in the development and manufacture of highly valued cardiac markers used ... scientific team's extensive expertise with protein chemistry has led to the development and ...
(Date:8/26/2015)... , Aug. 26, 2015 Intrexon Corporation (NYSE: ... today the closing of its previously announced public offering ... the underwriters of their option to purchase an additional ... price of $41.00 per share.  The exercise of the ... common stock sold by Intrexon to 5,609,756 shares and ...
Breaking Biology Technology:METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 2Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 3Intrexon Announces Closing of $230 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares 4
... PRINCETON, N.J., March 3 BioWa, Inc. ... agreement with Genentech, Inc. providing,Genentech additional access ... development of select antibodies for potential therapeutic,applications ... "BioWa is pleased to extend this ...
... 29 For the first time,researchers at North ... whose halves are physically or chemically,different -- so-called ... an alternating electrical field is applied to liquid,surrounding ... published in the Feb. 8, 2008, edition,of Physical ...
... - AEterna Zentaris Inc.,(NASDAQ: AEZS ; ... on,endocrine therapy and oncology, today announced the ... Vice President, Administrative & Legal,Affairs and Corporate ... of,Vice President and Chief Financial Officer of ...
Cached Biology Technology:BioWa Announces Expansion of License Agreement with Genentech for BioWa's POTELLIGENT(R) Technology 2'Two-Faced' Particles Act Like Tiny Submarines 2'Two-Faced' Particles Act Like Tiny Submarines 3AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs 2
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... 2008, Cambridge, UK Any way you slice it, ... , The planarian, a flatworm normally living in ... a single planarian cut into 200 pieces can generate ... is not merely a fascinating master of regeneration, but can ...
... Hosted by Weill Cornell Medical College, the Ansary Symposium ... of leading figures in the field, including internationally known ... and ethical issues in stem cell research. ... -, Thursday, September 18, 8:00 AM-1:30 PM ...
... release is available in French . , Researchers ... of the Jewish General Hospital along with colleagues at ... (OHRI) report a significant breakthrough in the use of viruses ... oncolytic virotherapy. Their results were published in the September early ...
Cached Biology News:Ansary Symposium on Stem Cell Research at Weill Cornell Medical College 2Viral 'magic bullet' targets cancer cells with help of new compound 2
A univariate (peak height or area) quantitative multi-component analysis package....
... The genus Salmonella is a member of ... Gram-negative bacilli that are facultative and flagellated (motile). ... flagellar antigen (phase 1 & 2), the "O" ... and the "Vi" or capsular antigen (referred to ...
... DW4 liquid handling system from Molecular Devices ... in one instrument. The system handles a ... plate washing96-, 384- and 1536-welland is the ... DW4 has been optimized to dispense from ...
... With 36 mg/L sodium pyruvate, 50 mg/L ... mg/L glucose, calcium chloride, and magnesium chloride. ... (BSS) in tissue culture is generally attributed ... 1885, Sydney Ringer developed a solution of ...
Biology Products: